Michael Craig Pine - 04 Dec 2023 Form 4/A - Amendment Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
04 Dec 2023
Net transactions value
-$442,890
Form type
4/A - Amendment
Filing time
11 Dec 2023, 16:15:33 UTC
Date Of Original Report
06 Dec 2023
Previous filing
22 Jun 2023
Next filing
09 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $567,900 +45,000 +842% $12.62 50,343 04 Dec 2023 Direct F1
transaction EYPT Common Stock Sale $990,000 -45,000 -89% $22.00 5,343 04 Dec 2023 Direct
transaction EYPT Common Stock Sale $20,790 -1,000 -19% $20.79 4,343 04 Dec 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -45,000 -45% $0.000000 55,000 04 Dec 2023 Common Stock 45,000 $12.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 This owned share transaction was inadvertently left off of the original Form 4 filing on December 6, 2023.
F3 The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.